Loading...
Market
What will be the market share of the new FDA-approved nasal spray compared to EpiPen by the end of 2024?
2
Resolution / Starting Odds
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Pharmaceutical market share data from publicly available financial reports or industry analysis
Story
FDA Approves Nasal Spray for Severe Allergies
Aug 21, 2024, 02:20 AM
The US Food and Drug Administration (FDA) has approved a new nasal spray device for administering epinephrine, the active ingredient in EpiPens, to treat severe allergies. This innovative approach offers an alternative to the traditional needle-based method, providing a potentially life-saving solution for patients who experience severe allergic reactions but are hesitant to use EpiPens. The nasal spray is designed to address both mild and severe allergies, marking a significant advancement in allergy treatment.
View original story
Similar markets
Less than 20% • 25%
20% to 40% • 25%
40% to 60% • 25%
More than 60% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 5% • 25%
5-10% • 25%
10-20% • 25%
More than 20% • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 20% • 25%
More than 20% • 25%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
<10% • 25%
10-25% • 25%
25-50% • 25%
>50% • 25%
Approved in UK only • 25%
Approved in UK and EU • 25%
Approved in UK, EU, and USA • 25%
Not approved in any major market • 25%
Less than 10% • 25%
10% to 30% • 25%
30% to 50% • 25%
More than 50% • 25%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%